Impact of targeting deviations on outcome in medulloblastoma. Update of the french medulloblastoma study group (French society of pediatric oncology)

PURPOSE: The French Society of Pediatric Oncology MDH82 study demonstrated the effectiveness of 20 Gy irradiation of involved fields after doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or mechlorethamine, vincristine, procarbazine, and prednisone/ABVD chemotherapy in children with localized Hodgkin’s disease (HD). The response to primary chemotherapy was the only predictor of survival. To reduce long-term treatment complications without compromising efficacy, the MDH90 study was based on a new chemotherapy regimen devoid of both alkylating agents and anthracycline, followed by 20 Gy of radiotherapy (RT) for good responders. PATIENTS AND METHODS: From January 1990 to July 1996, 202 children were enrolled from 30 institutions. Good responders to four cycles of vinblastine, bleomycin, etoposide (VP16), and prednisone (VBVP) were given 20 Gy of RT and no further therapy. Poor responders were given vincristine, procarbazine, prednisone, and doxorubicin. After a second evaluation, good responders were given 20 Gy of RT, and poor responders were given 40 Gy of RT. RESULTS: One hundred seventy-one patients (85%) were good responders to VBVP, 27 (15%) were poor responders, and four did not respond. With a median follow-up of 74 months (range, 25 to 117 months), the 5-year overall survival rate (mean ± SD) is 97.5% ± 2.1%, and the event-free survival rate (mean ± SD) is 91.1% ± 1.8%. Significant predictors of worse event-free survival in multivariate analysis were hemoglobin < 10.5 g/L, “b” biologic class, and nodular sclerosis. CONCLUSION: These results suggest that most children with clinical stage I and II HD can be treated with chemotherapy devoid of alkylating agents and anthracycline, followed by low-dose RT.

Download Full-text

Testicular Disease in Childhood B-Cell Non-Hodgkin’s Lymphoma: The French Society of Pediatric Oncology Experience

Journal of Clinical Oncology ◽

10.1200/jco.2001.19.9.2397 ◽

2001 ◽

Vol 19 (9) ◽

pp. 2397-2403 ◽

Cited By ~ 21

Author(s):

Jean-Hugues Dalle ◽

Françoise Mechinaud ◽

Jean Michon ◽

Jean-Claude Gentet ◽

Lionel de Lumley ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

B Cell ◽

Pediatric Oncology ◽

Hodgkin’S Lymphoma ◽

Lymphoblastic Leukemia ◽

Hodgkin's Lymphoma ◽

French Society ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Testicular Disease

PURPOSE: To investigate whether testicular disease in childhood B-cell lymphoma should continue to be considered a sanctuary site, as it is with other lymphoid malignancies such as acute lymphoblastic leukemia. PATIENTS AND METHODS: Seven hundred forty-two children with B-cell non-Hodgkin’s lymphoma were included in the LMB protocols of the French Society of Pediatric Oncology from February 1981 to May 1994. Thirty patients (5.3%) had testicular involvement at diagnosis. We describe the clinical presentation and outcome of these 30 patients, who were treated without local radiation therapy. RESULTS: Five patients underwent diagnostic orchidectomy. The median patient age was 8.5 years (range, 2 to 14 years), and their cancers were stage III (18 patients), stage IV (five patients), and B-cell acute lymphoblastic leukemia (seven patients). Five patients had central nervous system involvement. Twenty-eight patients (95%) achieved complete remission. Twenty-six patients are alive without progressive disease (median follow-up, 6.5 years). CONCLUSION: Testicular disease does not seem to confer a poor prognosis, and it is curable with intensive combination chemotherapy alone. Local treatment (surgery or radiation) is avoidable; therefore, gonadal function can be preserved.

Download Full-text

Incidence of Horner syndrome associated with neuroblastic disease

Child s Nervous System ◽

10.1007/s00381-020-04966-z ◽

2020 ◽

Author(s):

Katarzyna Kuchalska ◽

Monika Barełkowska ◽

Katarzyna Derwich ◽

Katarzyna Jończyk-Potoczna ◽

Anna Gotz-Więckowska

Keyword(s):

Adrenal Gland ◽

Retrospective Analysis ◽

Surgical Procedures ◽

Pediatric Oncology ◽

Surgical Procedure ◽

Pediatric Patients ◽

Study Group ◽

Horner Syndrome ◽

Neuroblastic Tumor ◽

Frequent Localization

Abstract Purpose Horner syndrome (HS) manifests in unilateral ptosis, miosis, enophthalmos, and anhedonia. It is most commonly caused by trauma or surgical procedures, but can also occur in pediatric patients as a result of tumors, especially neuroblastoma (NBL). The objective of this study was to analyze the incidence of HS in patients diagnosed with NBL. Methods A retrospective analysis of data collected at the Department of Pediatric Oncology, Hematology, and Transplantology from 2004 to 2019 was performed. The study group included 119 patients younger than 18 years old, with 62 girls and 57 boys. All of them were diagnosed with a neuroblastic tumor. Results Among the 119 patients, eight children (6.72%) were diagnosed with HS associated with NBL. Three of these patients presented to the clinic with HS, whereas HS developed after the surgical procedure to remove the tumor in four patients. The adrenal gland was the most frequent localization of the tumor. However, HS occurred more frequently in patients with mediastinum tumors. As a presenting symptom, HS occurred in 2 of 11 cases (18.18%) with mediastinum localization. All of the patients with HS were younger than 2 years old. Conclusion Investigation of the cause of isolated HS is crucial because it can be the first symptom of NBL. However, the surgical procedure itself increases the risk of HS as a complication of NBL treatment.

Download Full-text

Neuroblastoma in infants aged less than 6 months: Is more aggressive treatment necessary? A report from the pediatric oncology study group of the Kyushu area

Journal of Pediatric Surgery ◽

10.1016/0022-3468(95)90699-1 ◽

1995 ◽

Vol 30 (5) ◽

pp. 715-721 ◽

Cited By ~ 6

Author(s):

S Suita ◽

Y Zaizen ◽

Y Sera ◽

H Takamatsu ◽

H Mizote ◽

...

Keyword(s):

Pediatric Oncology ◽

Study Group ◽

Aggressive Treatment

Download Full-text

Primary mediastinal and retroperitoneal malignant germ cell tumors in children and adolescents: Results of the TGM95 trial, a study of the French Society of Pediatric Oncology (Société Française des Cancers de l'Enfant)

Pediatric Blood & Cancer ◽

10.1002/pbc.26494 ◽

2017 ◽

Vol 64 (9) ◽

pp. e26494 ◽

Cited By ~ 7

Author(s):

Hélène Sudour-Bonnange ◽

Cécile Faure-Conter ◽

Hélène Martelli ◽

Frederic Hameury ◽

Brice Fresneau ◽

...

Keyword(s):

Germ Cell ◽

Children And Adolescents ◽

Pediatric Oncology ◽

Germ Cell Tumors ◽

French Society ◽

Malignant Germ Cell Tumors

Download Full-text

Impact of the First Wave of COVID-19 on Pediatric Oncology and Hematology: A Report from the French Society of Pediatric Oncology

Cancers ◽

10.3390/cancers12113398 ◽

2020 ◽

Vol 12 (11) ◽

pp. 3398

Author(s):

Jérémie Rouger-Gaudichon ◽

Eric Thébault ◽

Arthur Félix ◽

Aurélie Phulpin ◽

Catherine Paillard ◽

...

Keyword(s):

Intensive Care Unit ◽

Stem Cell ◽

Intensive Care ◽

Pediatric Oncology ◽

Medical Records ◽

Hematological Malignancy ◽

Radiological Finding ◽

French Society ◽

Hematopoietic Stem ◽

Children And Young Adults

Data regarding coronavirus disease 2019 (COVID-19) description are still limited in pediatric oncology. The French society of pediatric oncology (SFCE) initiated a study to better describe COVID-19 in patients followed in French pediatric oncology and hematology wards. All patients diagnosed with COVID-19 and followed in a SFCE center were enrolled. Data from medical records were analyzed for all patients enrolled up to the end of May 2020. Data were available for 37 patients. Thirty-one were children under 18 years of age. Nineteen patients were female. Seventeen patients had a solid tumor, 16 had a hematological malignancy and four recently underwent hematopoietic stem cell transplantation (HSCT) for non-oncological conditions. Twenty-eight patients presented symptoms, most often with fever, cough, rhinorrhea and asthenia. Ground-glass opacities were the most frequent radiological finding with abnormalities mostly bilateral and peripherally distributed. Twenty-four patients received chemotherapy a month prior to COVID-19 diagnosis. Most patients did not require hospitalization. Three patients required oxygen at the time of diagnosis. In total, five patients were admitted in an intensive care unit because of COVID-19 and one died from the disease. Children and young adults treated for a cancer and/or with a HSCT may be at risk for severe COVID-19 and should be closely monitored.

Download Full-text